Anuh Pharma Ltd Gains 0.25% Today Amid Broader Market Decline, Faces 22.05% Three-Month Drop

Anuh Pharma Ltd is currently witnessing strong buying activity, with the stock showing a modest gain of 0.25% today, contrasting with the Sensex’s decline of 0.14%. Over the past week, Anuh Pharma has recorded a total increase of 0.66%, outperforming the Sensex, which rose by 0.55%. However, the stock’s performance over the longer term reveals challenges, with a 3-month decline of 22.05% compared to the Sensex’s drop of 2.85%.

Despite the recent uptick, Anuh Pharma’s year-to-date performance remains negative at -26.12%, while the Sensex has gained 3.49% during the same period. The stock has not experienced any consecutive gains recently, maintaining a flat return of 0% over the last few days.

Price summary indicates that Anuh Pharma opened with a gap up, but it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. The buying pressure may be attributed to market sentiment or specific developments within the pharmaceutical sector, although no specific events have been detailed.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23